MedTrace Logo

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

NCT02343718 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.

Conditions

Interventions

DRUG

Vinblastine

DRUG

Temsirolimus

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Sylvain Baruchel · Hospital for Sick Children, Toronto ON Canada

  • Rebecca Deyell · Children's & Women's Health Centre of BC Branch, Vancouver BC, Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-24
Primary Completion
2017-09-28
Completion
2019-01-16

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02343718 on ClinicalTrials.gov